Vuorma Sirkku, Teperi Juha, Aalto Anna-Mari, Hurskainen Ritva, Kujansuu Erkki, Rissanen Pekka
National R and D Centre for Welfare and Health, Helsinki, Finland.
Health Expect. 2004 Dec;7(4):327-37. doi: 10.1111/j.1369-7625.2004.00297.x.
To evaluate the effects of a decision aid for menorrhagia on treatment outcomes and costs over a 12-month follow-up.
Randomized trial and pre-trial prospective cohort study.
Gynaecology outpatient clinics in 14 Finnish hospitals, 363 (randomized trial) plus 206 (cohort study) patients with menorrhagia.
A decision aid booklet explaining menorrhagia and treatment options, mailed to patients before their first clinic appointment.
Health related quality of life, psychological well-being, menstrual symptoms, satisfaction with treatment outcome, use and cost of health care services.
All study groups experienced overall improvement in health-related quality of life, anxiety, and psychosomatic and menstrual symptoms, but not in sexual life. Treatment in the intervention group was more active than in the control group, with more frequent course of medication and less undecided treatments. However, there were no marked disparities in health outcomes, satisfaction with treatment outcome and costs. Total costs (including productivity loss) per woman because of menorrhagia over the 12-month follow-up were 2760 and 3094 in the intervention and control group, respectively (P = 0.1). The pre-trial group also had a significantly lower rate of uterus saving surgery compared with the control group, but no difference in costs because of menorrhagia treatment.
Despite some differences in treatment courses, a decision aid for menorrhagia in booklet form did not increase the use of health services or treatment costs, nor had it impact on health outcomes or satisfaction with outcome of treatment.
评估月经过多决策辅助工具对12个月随访期内治疗结果和成本的影响。
随机试验和试验前前瞻性队列研究。
芬兰14家医院的妇科门诊,363名(随机试验)加206名(队列研究)月经过多患者。
一本解释月经过多及治疗选择的决策辅助手册,在患者首次门诊预约前邮寄给他们。
健康相关生活质量、心理健康、月经症状、对治疗结果的满意度、医疗服务的使用情况和成本。
所有研究组在健康相关生活质量、焦虑、身心症状和月经症状方面总体均有改善,但性生活方面未改善。干预组的治疗比对照组更积极,用药疗程更频繁,未决治疗更少。然而,在健康结果、对治疗结果的满意度和成本方面没有明显差异。在12个月的随访期内,干预组和对照组因月经过多导致的每名女性的总成本(包括生产力损失)分别为2760和3094(P = 0.1)。试验前组与对照组相比,子宫保留手术率也显著较低,但因月经过多治疗的成本没有差异。
尽管治疗过程存在一些差异,但手册形式的月经过多决策辅助工具并未增加医疗服务的使用或治疗成本,对健康结果或对治疗结果的满意度也没有影响。